Puma Biotechnology Announces Underwriters’ Full Exercise Of Option To Purchase Additional Shares

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced that the underwriters for its public offering of 1,000,000 shares of its common stock at $190.00 per share have elected to exercise in full their option to purchase up to an additional 150,000 shares of common stock at the public offering price, less the underwriting discount. The closing for the additional purchase of 150,000 shares is expected to take place concurrently with the closing for the initial purchase of 1,000,000 shares on January 27, 2015, subject to customary closing conditions.

Help employers find you! Check out all the jobs and post your resume.